CA2621167A1 - Regulation of mineral and skeletal metabolism - Google Patents
Regulation of mineral and skeletal metabolism Download PDFInfo
- Publication number
- CA2621167A1 CA2621167A1 CA002621167A CA2621167A CA2621167A1 CA 2621167 A1 CA2621167 A1 CA 2621167A1 CA 002621167 A CA002621167 A CA 002621167A CA 2621167 A CA2621167 A CA 2621167A CA 2621167 A1 CA2621167 A1 CA 2621167A1
- Authority
- CA
- Canada
- Prior art keywords
- composition
- levels
- pth
- manufactured
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000004060 metabolic process Effects 0.000 title description 14
- 229910052500 inorganic mineral Inorganic materials 0.000 title description 8
- 239000011707 mineral Substances 0.000 title description 8
- 230000033228 biological regulation Effects 0.000 title description 7
- 102000003982 Parathyroid hormone Human genes 0.000 claims abstract description 158
- 108090000445 Parathyroid hormone Proteins 0.000 claims abstract description 158
- 239000000199 parathyroid hormone Substances 0.000 claims abstract description 158
- 229960001319 parathyroid hormone Drugs 0.000 claims abstract description 158
- 239000011575 calcium Substances 0.000 claims abstract description 127
- 239000000203 mixture Substances 0.000 claims abstract description 57
- 238000000034 method Methods 0.000 claims abstract description 53
- 229910019142 PO4 Inorganic materials 0.000 claims abstract description 39
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims abstract description 39
- 239000010452 phosphate Substances 0.000 claims abstract description 38
- 230000000694 effects Effects 0.000 claims abstract description 34
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract description 26
- 229910052791 calcium Inorganic materials 0.000 claims abstract description 26
- 238000009472 formulation Methods 0.000 claims abstract description 24
- 238000002347 injection Methods 0.000 claims description 25
- 239000007924 injection Substances 0.000 claims description 25
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 22
- 210000000988 bone and bone Anatomy 0.000 claims description 18
- 150000001413 amino acids Chemical class 0.000 claims description 14
- 239000012634 fragment Substances 0.000 claims description 14
- 210000001519 tissue Anatomy 0.000 claims description 14
- 208000020832 chronic kidney disease Diseases 0.000 claims description 13
- 230000001603 reducing effect Effects 0.000 claims description 13
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 12
- 241000588724 Escherichia coli Species 0.000 claims description 11
- 230000001419 dependent effect Effects 0.000 claims description 11
- 239000011734 sodium Substances 0.000 claims description 11
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 9
- 210000004027 cell Anatomy 0.000 claims description 9
- 229910052708 sodium Inorganic materials 0.000 claims description 9
- 201000002980 Hyperparathyroidism Diseases 0.000 claims description 8
- 201000005991 hyperphosphatemia Diseases 0.000 claims description 7
- 208000013725 Chronic Kidney Disease-Mineral and Bone disease Diseases 0.000 claims description 5
- 208000005770 Secondary Hyperparathyroidism Diseases 0.000 claims description 5
- 201000006409 renal osteodystrophy Diseases 0.000 claims description 5
- 210000005233 tubule cell Anatomy 0.000 claims description 5
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 4
- 230000000968 intestinal effect Effects 0.000 claims description 4
- 208000037147 Hypercalcaemia Diseases 0.000 claims description 3
- 102000003673 Symporters Human genes 0.000 claims description 3
- 108090000088 Symporters Proteins 0.000 claims description 3
- ZQBZAOZWBKABNC-UHFFFAOYSA-N [P].[Ca] Chemical compound [P].[Ca] ZQBZAOZWBKABNC-UHFFFAOYSA-N 0.000 claims description 3
- 230000000148 hypercalcaemia Effects 0.000 claims description 3
- 208000030915 hypercalcemia disease Diseases 0.000 claims description 3
- 238000013268 sustained release Methods 0.000 claims description 3
- 239000012730 sustained-release form Substances 0.000 claims description 3
- 241000699802 Cricetulus griseus Species 0.000 claims description 2
- 230000002611 ovarian Effects 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 230000002730 additional effect Effects 0.000 claims 2
- 230000031891 intestinal absorption Effects 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 239000002831 pharmacologic agent Substances 0.000 claims 1
- 238000005259 measurement Methods 0.000 abstract description 8
- 150000001875 compounds Chemical class 0.000 abstract description 2
- 210000002966 serum Anatomy 0.000 description 61
- 101001055531 Homo sapiens Matrix extracellular phosphoglycoprotein Proteins 0.000 description 52
- 102100026142 Matrix extracellular phosphoglycoprotein Human genes 0.000 description 46
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 20
- 230000036470 plasma concentration Effects 0.000 description 18
- 102100024802 Fibroblast growth factor 23 Human genes 0.000 description 17
- 101001051973 Homo sapiens Fibroblast growth factor 23 Proteins 0.000 description 14
- 201000010099 disease Diseases 0.000 description 14
- 210000004369 blood Anatomy 0.000 description 13
- 239000008280 blood Substances 0.000 description 13
- 210000002990 parathyroid gland Anatomy 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 12
- 230000013632 homeostatic process Effects 0.000 description 12
- 230000009103 reabsorption Effects 0.000 description 12
- 230000009467 reduction Effects 0.000 description 12
- 238000011282 treatment Methods 0.000 description 12
- 208000005072 Oncogenic osteomalacia Diseases 0.000 description 11
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- 241000700159 Rattus Species 0.000 description 9
- 229940088597 hormone Drugs 0.000 description 9
- 239000005556 hormone Substances 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 210000001124 body fluid Anatomy 0.000 description 8
- 239000010839 body fluid Substances 0.000 description 8
- 230000001276 controlling effect Effects 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 230000001105 regulatory effect Effects 0.000 description 8
- 210000005239 tubule Anatomy 0.000 description 8
- 210000002700 urine Anatomy 0.000 description 8
- 229960005084 calcitriol Drugs 0.000 description 7
- 235000020964 calcitriol Nutrition 0.000 description 7
- 239000011612 calcitriol Substances 0.000 description 7
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 7
- 102000048750 human MEPE Human genes 0.000 description 7
- 210000003734 kidney Anatomy 0.000 description 7
- 230000007246 mechanism Effects 0.000 description 7
- 230000028327 secretion Effects 0.000 description 7
- 239000000556 agonist Substances 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 5
- 208000005050 Familial Hypophosphatemic Rickets Diseases 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 108010076504 Protein Sorting Signals Proteins 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 208000031878 X-linked hypophosphatemia Diseases 0.000 description 5
- 208000035724 X-linked hypophosphatemic rickets Diseases 0.000 description 5
- 239000005557 antagonist Substances 0.000 description 5
- 230000008416 bone turnover Effects 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 229940109239 creatinine Drugs 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 210000000936 intestine Anatomy 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 208000006386 Bone Resorption Diseases 0.000 description 4
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 4
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 4
- 108090000569 Fibroblast Growth Factor-23 Proteins 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 230000024279 bone resorption Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 102000055006 Calcitonin Human genes 0.000 description 3
- 108060001064 Calcitonin Proteins 0.000 description 3
- 241000282465 Canis Species 0.000 description 3
- 101000864793 Homo sapiens Secreted frizzled-related protein 4 Proteins 0.000 description 3
- 208000029663 Hypophosphatemia Diseases 0.000 description 3
- 241000282553 Macaca Species 0.000 description 3
- 101000684728 Mus musculus Secreted frizzled-related sequence protein 4 Proteins 0.000 description 3
- 208000035977 Rare disease Diseases 0.000 description 3
- 102100030052 Secreted frizzled-related protein 4 Human genes 0.000 description 3
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 3
- 230000009102 absorption Effects 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000008827 biological function Effects 0.000 description 3
- 230000010072 bone remodeling Effects 0.000 description 3
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 3
- 229960004015 calcitonin Drugs 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 210000000963 osteoblast Anatomy 0.000 description 3
- 208000005368 osteomalacia Diseases 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- -1 urine Substances 0.000 description 3
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 3
- 235000005282 vitamin D3 Nutrition 0.000 description 3
- 239000011647 vitamin D3 Substances 0.000 description 3
- 229940021056 vitamin d3 Drugs 0.000 description 3
- 208000020084 Bone disease Diseases 0.000 description 2
- 206010065687 Bone loss Diseases 0.000 description 2
- 208000004434 Calcinosis Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 102000013830 Calcium-Sensing Receptors Human genes 0.000 description 2
- 108010050543 Calcium-Sensing Receptors Proteins 0.000 description 2
- 102000034534 Cotransporters Human genes 0.000 description 2
- 108020003264 Cotransporters Proteins 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- 208000000381 Familial Hypophosphatemia Diseases 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 101100345095 Mus musculus Mepe gene Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 101100345096 Rattus norvegicus Mepe gene Proteins 0.000 description 2
- 230000033558 biomineral tissue development Effects 0.000 description 2
- 230000036765 blood level Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 230000002308 calcification Effects 0.000 description 2
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 description 2
- 230000004094 calcium homeostasis Effects 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- 239000000515 collagen sponge Substances 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 230000000994 depressogenic effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 210000002997 osteoclast Anatomy 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 210000000512 proximal kidney tubule Anatomy 0.000 description 2
- 208000007442 rickets Diseases 0.000 description 2
- 238000012453 sprague-dawley rat model Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004042 Fibroblast Growth Factor-23 Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 229910017569 La2(CO3)3 Inorganic materials 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 101710184030 Matrix extracellular phosphoglycoprotein Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 101150071808 PTHLH gene Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 208000005475 Vascular calcification Diseases 0.000 description 1
- 108010020277 WD repeat containing planar cell polarity effector Proteins 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000004159 blood analysis Methods 0.000 description 1
- 230000002092 calcimimetic effect Effects 0.000 description 1
- 239000001639 calcium acetate Substances 0.000 description 1
- 229960005147 calcium acetate Drugs 0.000 description 1
- 235000011092 calcium acetate Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 230000003913 calcium metabolism Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 108010030445 carboxyl-terminal parathyroid hormone Proteins 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- VDHAWDNDOKGFTD-MRXNPFEDSA-N cinacalcet Chemical compound N([C@H](C)C=1C2=CC=CC=C2C=CC=1)CCCC1=CC=CC(C(F)(F)F)=C1 VDHAWDNDOKGFTD-MRXNPFEDSA-N 0.000 description 1
- 229960003315 cinacalcet Drugs 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 201000000523 end stage renal failure Diseases 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000005048 flame photometry Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 229940099065 fosrenol Drugs 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000001434 glomerular Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 231100000508 hormonal effect Toxicity 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- NZPIUJUFIFZSPW-UHFFFAOYSA-H lanthanum carbonate Chemical compound [La+3].[La+3].[O-]C([O-])=O.[O-]C([O-])=O.[O-]C([O-])=O NZPIUJUFIFZSPW-UHFFFAOYSA-H 0.000 description 1
- 229960001633 lanthanum carbonate Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 208000027361 mineral metabolism disease Diseases 0.000 description 1
- 210000004898 n-terminal fragment Anatomy 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 238000002663 nebulization Methods 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 230000000849 parathyroid Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000006320 pegylation Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000008288 physiological mechanism Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 230000018406 regulation of metabolic process Effects 0.000 description 1
- 229940020428 renagel Drugs 0.000 description 1
- 230000008060 renal absorption Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- ZNSIZMQNQCNRBW-UHFFFAOYSA-N sevelamer Chemical compound NCC=C.ClCC1CO1 ZNSIZMQNQCNRBW-UHFFFAOYSA-N 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 208000028198 tertiary hyperparathyroidism Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 230000008427 tissue turnover Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 210000000515 tooth Anatomy 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 238000005353 urine analysis Methods 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US71315405P | 2005-08-30 | 2005-08-30 | |
| US60/713,154 | 2005-08-30 | ||
| US71711505P | 2005-09-13 | 2005-09-13 | |
| US60/717,115 | 2005-09-13 | ||
| US80779706P | 2006-07-19 | 2006-07-19 | |
| US60/807,797 | 2006-07-19 | ||
| PCT/US2006/033133 WO2007027510A2 (en) | 2005-08-30 | 2006-08-23 | Regulation of mineral and skeletal metabolism |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2621167A1 true CA2621167A1 (en) | 2007-03-08 |
Family
ID=37809379
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002621167A Abandoned CA2621167A1 (en) | 2005-08-30 | 2006-08-23 | Regulation of mineral and skeletal metabolism |
Country Status (6)
| Country | Link |
|---|---|
| US (6) | US20070066514A1 (enExample) |
| EP (1) | EP1937064A4 (enExample) |
| JP (1) | JP2009511426A (enExample) |
| AU (1) | AU2006285127A1 (enExample) |
| CA (1) | CA2621167A1 (enExample) |
| WO (1) | WO2007027510A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5645408B2 (ja) * | 2006-11-16 | 2014-12-24 | カイ ファーマシューティカルズ インコーポレーティッド | 副甲状腺機能亢進症および高カルシウム血症性障害の治療のためのポリカチオン性カルシウムモジュレーターペプチド |
| DK3192520T3 (da) * | 2009-07-29 | 2019-05-27 | Kai Pharmaceuticals Inc | Terapeutiske midler til reducering af niveauerne af parathyreoideahormon |
| WO2012001523A2 (en) * | 2010-07-01 | 2012-01-05 | Goji Ltd. | Processing objects by radio frequency (rf) energy |
| RS55503B1 (sr) | 2011-06-08 | 2017-05-31 | Kai Pharmaceuticals Inc | Terapijska sredstva za regulisanje fosfora u serumu |
| RU2730997C1 (ru) * | 2020-03-10 | 2020-08-26 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Самарский государственный медицинский университет" Министерства здравоохранения Российской Федерации | Способ диагностики первичного гиперпаратиреоза |
| RU2730999C1 (ru) * | 2020-03-10 | 2020-08-26 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Самарский государственный медицинский университет" Министерства здравоохранения Российской Федерации | Способ биохимической диагностики первичного гиперпаратиреоза |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5384313A (en) * | 1993-11-24 | 1995-01-24 | Wisconsin Alumni Research Foundation | 21-norvitamin D compounds |
| CA2329054C (en) * | 1998-05-18 | 2011-03-08 | University College London | A novel polypeptide hormone phosphatonin |
| US6673900B2 (en) * | 1999-11-04 | 2004-01-06 | University College London | Polypeptide hormone-phosphatonin |
| EP1207896A4 (en) * | 1999-09-02 | 2004-09-08 | Acologix Inc | METHOD AND COMPOSITIONS FOR REDUCING THE SERUM PHOSPHATE MIRROR |
| US6790639B2 (en) * | 2000-02-29 | 2004-09-14 | Pfizer Inc. | Mammalian osteoregulins |
| US6264987B1 (en) * | 2000-05-19 | 2001-07-24 | Alkermes Controlled Therapeutics Inc. Ii | Method for preparing microparticles having a selected polymer molecular weight |
| AU2001274566A1 (en) * | 2000-06-21 | 2002-01-02 | Takeda Chemical Industries Ltd. | Novel protein and dna thereof |
| US20040048837A1 (en) * | 2002-09-06 | 2004-03-11 | Lazarus J. Michael | Method for treatment of renal disease |
| WO2005028504A2 (en) * | 2003-09-19 | 2005-03-31 | Board Of Regents, The University Of Texas System | Regulation of tissue mineralization and phosphate met abolism by asarm peptides |
-
2006
- 2006-08-23 WO PCT/US2006/033133 patent/WO2007027510A2/en not_active Ceased
- 2006-08-23 CA CA002621167A patent/CA2621167A1/en not_active Abandoned
- 2006-08-23 EP EP06802277A patent/EP1937064A4/en not_active Withdrawn
- 2006-08-23 AU AU2006285127A patent/AU2006285127A1/en not_active Abandoned
- 2006-08-23 US US11/466,673 patent/US20070066514A1/en not_active Abandoned
- 2006-08-23 JP JP2008529121A patent/JP2009511426A/ja active Pending
-
2007
- 2007-10-29 US US11/926,716 patent/US20090018064A1/en not_active Abandoned
- 2007-10-29 US US11/926,460 patent/US20090029915A1/en not_active Abandoned
- 2007-10-29 US US11/926,719 patent/US20090023633A1/en not_active Abandoned
- 2007-10-29 US US11/926,726 patent/US20090023634A1/en not_active Abandoned
-
2010
- 2010-12-14 US US12/967,888 patent/US20110251124A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20090023633A1 (en) | 2009-01-22 |
| AU2006285127A8 (en) | 2008-07-24 |
| US20090023634A1 (en) | 2009-01-22 |
| US20090029915A1 (en) | 2009-01-29 |
| JP2009511426A (ja) | 2009-03-19 |
| EP1937064A4 (en) | 2009-09-16 |
| WO2007027510A2 (en) | 2007-03-08 |
| US20110251124A1 (en) | 2011-10-13 |
| EP1937064A2 (en) | 2008-07-02 |
| AU2006285127A1 (en) | 2007-03-08 |
| US20090018064A1 (en) | 2009-01-15 |
| WO2007027510A3 (en) | 2008-01-10 |
| US20070066514A1 (en) | 2007-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7209382B2 (ja) | 心不全の治療用組成物 | |
| US10898549B2 (en) | Methods for treating hypophosphatasia in adolescents and adults | |
| JP2023144124A (ja) | 骨格異形成症を処置するためのｃ型ナトリウム利尿ペプチド変異体の使用 | |
| RU2225221C2 (ru) | ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ Эритропоэтина | |
| US20110251124A1 (en) | Regulation of mineral and skeletal metabolism | |
| MXPA04006728A (es) | Tratamiento de desordenes oseos con medicamentos anabolicos esqueleticos. | |
| WO2017171871A1 (en) | Methods for treating hypophosphatasia in adolescents and adults | |
| EP4366758A1 (en) | C-type natriuretic peptide variants to treat skeletal dysplasia in children | |
| US20040082588A1 (en) | Methods for treating disorders of calcium homeostasis | |
| US20160271265A1 (en) | Insulin-like growth factor mimetics for use in therapy | |
| US20250032576A1 (en) | CNP Therapy | |
| LU100168B1 (en) | Prevention of Bone and Mineral Disorders by Restoring Calcium and Phosphate Homeostasis in Patients Suffering from Chronic Kidney Disease | |
| US12514906B2 (en) | Use of C-type natriuretic peptide variants to treat skeletal dysplasia | |
| CN101282640A (zh) | 矿物与骨骼代谢的调节 | |
| HK40074481A (en) | Use of c-type natriuretic peptide variants to treat skeletal dysplasia | |
| CN117881416A (zh) | 用于治疗儿童的骨骼发育不良的c型利钠肽变体 | |
| WO2025076498A1 (en) | Treatment of osteogenesis imperfecta with c-type natriuretic peptide and analogs thereof | |
| HK1255864B (en) | Use of c-type natriuretic peptide variants to treat skeletal dysplasia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |